pioglitazone has been researched along with Blood Poisoning in 10 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Male rats were randomly divided into three groups as follows: sham, sepsis, and sepsis + pioglitazone." | 7.81 | Protective effect of pioglitazone on sepsis-induced intestinal injury in a rodent model. ( Gao, M; Jiang, Y; Peng, Y; Xiao, X; Yang, M, 2015) |
| "The insulin sensitizing thiazolidinedione drugs, rosiglitazone and pioglitazone are specific peroxisome proliferator-activated receptor-gamma agonists and reduce pro-inflammatory responses in patients with type 2 diabetes and coronary artery disease, and may be beneficial in sepsis." | 7.80 | Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis. ( Chima, R; Kaplan, J; Nowell, M; Zingarelli, B, 2014) |
| "To determine whether peroxisome proliferator-activated receptor (PPAR) gamma ligands improve survival of patients with septic shock we treated a mouse model of sepsis [apolipoprotein (Apo) E) knockout mice] with pioglitazone, a PPAR-gamma ligand." | 7.74 | Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis. ( Haraguchi, G; Imai, T; Isobe, M; Kosuge, H; Maejima, Y; Suzuki, J; Yoshida, M, 2008) |
| "Treatment with pioglitazone significantly inhibited the increases in the serum interleukin-6 and monocyte chemoattractant protein-1 (MCP-1) levels after CLP and lowered the mRNA expressions of proinflammatory cytokines, interleukin-6, and MCP-1 in omental tissue after CLP." | 5.37 | Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture. ( Kutsukake, M; Matsuda, A; Matsutani, T; Sasajima, K; Tamura, K; Tsujimura, Y; Uchida, E, 2011) |
| "Pioglitazone improves sepsis-induced organ injury accompanied with anti-inflammatory effects on visceral adipose tissue." | 3.85 | Impact of Pioglitazone on Macrophage Dynamics in Adipose Tissues of Cecal Ligation and Puncture-Treated Mice. ( Kutsukake, M; Matsuda, A; Matsutani, T; Tachikawa, E; Tamura, K; Uchida, E, 2017) |
| "Male rats were randomly divided into three groups as follows: sham, sepsis, and sepsis + pioglitazone." | 3.81 | Protective effect of pioglitazone on sepsis-induced intestinal injury in a rodent model. ( Gao, M; Jiang, Y; Peng, Y; Xiao, X; Yang, M, 2015) |
| "The insulin sensitizing thiazolidinedione drugs, rosiglitazone and pioglitazone are specific peroxisome proliferator-activated receptor-gamma agonists and reduce pro-inflammatory responses in patients with type 2 diabetes and coronary artery disease, and may be beneficial in sepsis." | 3.80 | Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis. ( Chima, R; Kaplan, J; Nowell, M; Zingarelli, B, 2014) |
| "Pioglitazone effectively prevents lung injury caused by CLP-induced sepsis by maintaining the anti-inflammatory status of visceral adipose tissue." | 3.80 | Pioglitazone attenuates lung injury by modulating adipose inflammation. ( Kobayashi, M; Kutsukake, M; Matsuda, A; Matsutani, T; Tachikawa, E; Tamura, K; Uchida, E, 2014) |
| " This utilized a single daily dose of pioglitazone for pediatric patients with severe sepsis and septic shock based upon adult and minimal adolescent data." | 3.77 | Optimal study design for pioglitazone in septic pediatric patients. ( Ding, L; Kaplan, J; Sherwin, CM; Spigarelli, MG; Vinks, AA, 2011) |
| "To determine whether peroxisome proliferator-activated receptor (PPAR) gamma ligands improve survival of patients with septic shock we treated a mouse model of sepsis [apolipoprotein (Apo) E) knockout mice] with pioglitazone, a PPAR-gamma ligand." | 3.74 | Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis. ( Haraguchi, G; Imai, T; Isobe, M; Kosuge, H; Maejima, Y; Suzuki, J; Yoshida, M, 2008) |
| "Treatment with pioglitazone significantly inhibited the increases in the serum interleukin-6 and monocyte chemoattractant protein-1 (MCP-1) levels after CLP and lowered the mRNA expressions of proinflammatory cytokines, interleukin-6, and MCP-1 in omental tissue after CLP." | 1.37 | Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture. ( Kutsukake, M; Matsuda, A; Matsutani, T; Sasajima, K; Tamura, K; Tsujimura, Y; Uchida, E, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsutani, T | 3 |
| Tamura, K | 3 |
| Kutsukake, M | 3 |
| Matsuda, A | 3 |
| Tachikawa, E | 2 |
| Uchida, E | 3 |
| Kaplan, JM | 1 |
| Zingarelli, B | 2 |
| Krallman, K | 1 |
| Tang Girdwood, S | 1 |
| Lagory, D | 1 |
| Mizuno, T | 1 |
| Fei, L | 1 |
| Wong, HR | 1 |
| Vinks, AA | 2 |
| Nakashima, M | 1 |
| Kinoshita, M | 1 |
| Nakashima, H | 1 |
| Kotani, A | 1 |
| Ishikiriyama, T | 1 |
| Kato, S | 1 |
| Hiroi, S | 1 |
| Seki, S | 1 |
| Kaplan, J | 2 |
| Nowell, M | 1 |
| Chima, R | 1 |
| Kobayashi, M | 1 |
| Gao, M | 1 |
| Jiang, Y | 1 |
| Xiao, X | 2 |
| Peng, Y | 1 |
| Yang, M | 1 |
| Shafaroodi, H | 1 |
| Hassanipour, M | 1 |
| Mousavi, Z | 1 |
| Rahimi, N | 1 |
| Dehpour, AR | 1 |
| Sherwin, CM | 1 |
| Ding, L | 1 |
| Spigarelli, MG | 1 |
| Tsujimura, Y | 1 |
| Sasajima, K | 1 |
| Haraguchi, G | 1 |
| Kosuge, H | 1 |
| Maejima, Y | 1 |
| Suzuki, J | 1 |
| Imai, T | 1 |
| Yoshida, M | 1 |
| Isobe, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetic Characteristics of Pioglitazone and Preliminary Biomarker Response in Adolescents Aged 12 to 17 Years With Severe Sepsis and Septic Shock[NCT01352182] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
We examined the effect of pioglitazone Area under the curve on IL-6 in patients receiving pioglitazone only. (Control subjects did not receive pioglitazone). The pharmacokinetic endpoint was area under the curve (AUC) total/days of pioglitazone administration (NCT01352182)
Timeframe: Evaluation of inflammatory biomarkers will be obtained prior to dosing for the first five days of the study
| Intervention | ng/ml (Least Squares Mean) |
|---|---|
| Pioglitazone Hydrochloride | -1.4425 |
| Normal Standard Care | NA |
The number of hypoglycemic events in pioglitazone vs standard care. Hypoglycemia was defined as blood glucose level that remains <40mg/dl despite dextrose bolus treatment. (NCT01352182)
Timeframe: Assessement over five days
| Intervention | events (Number) |
|---|---|
| Pioglitazone Hydrochloride | 0 |
| Normal Standard Care | 0 |
Pioglitazone concentration as the total area under curve divided by the number of days receiving the drug in subjects who took the drug by mouth versus by naso-gastric tube (NCT01352182)
Timeframe: five days
| Intervention | ng*h/ml (Mean) |
|---|---|
| Pioglitazone Hydrochloride by Mouth | 5363 |
| Pioglitazone Hydrochloride by Nasogastric Tube | 1052 |
ALT levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study
| Intervention | U/L (Median) |
|---|---|
| Pioglitazone Hydrochloride | 21.5 |
| Normal Standard Care | 24.5 |
BUN levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study
| Intervention | mg/dl (Median) |
|---|---|
| Pioglitazone Hydrochloride | 7.5 |
| Normal Standard Care | 10 |
Creatinine levels in blood from subject on the final day of enrollment (NCT01352182)
Timeframe: Final day of study
| Intervention | mg/dl (Median) |
|---|---|
| Pioglitazone Hydrochloride | 0.72 |
| Normal Standard Care | 0.415 |
1 trial available for pioglitazone and Blood Poisoning
| Article | Year |
|---|---|
Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial.
Topics: Critical Illness; Female; Humans; Hypoglycemic Agents; Male; Pioglitazone; Sepsis | 2018 |
9 other studies available for pioglitazone and Blood Poisoning
| Article | Year |
|---|---|
Impact of Pioglitazone on Macrophage Dynamics in Adipose Tissues of Cecal Ligation and Puncture-Treated Mice.
Topics: Adipokines; Animals; Arginase; Biomarkers; Cecum; Chemokine CCL2; Hypoglycemic Agents; Injections, I | 2017 |
Pioglitazone improves phagocytic activity of liver recruited macrophages in elderly mice possibly by promoting glucose catabolism.
Topics: Aging; Animals; CD11b Antigen; Cytokines; Escherichia coli; Escherichia coli Infections; Glucose; In | 2019 |
Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis.
Topics: Adipokines; Animals; Cytokines; Hypoglycemia; Hypoglycemic Agents; I-kappa B Proteins; Inflammation; | 2014 |
Pioglitazone attenuates lung injury by modulating adipose inflammation.
Topics: Acute Lung Injury; Adipose Tissue; Animals; Apoptosis; Disease Models, Animal; Endotoxins; Hypoglyce | 2014 |
Protective effect of pioglitazone on sepsis-induced intestinal injury in a rodent model.
Topics: Amine Oxidase (Copper-Containing); Animals; Bacterial Translocation; Disease Models, Animal; Interle | 2015 |
The Effects of Sub-Chronic Treatment with Pioglitazone on the Septic Mice Mortality in the Model of Cecal Ligation and Puncture: Involvement of Nitric Oxide Pathway.
Topics: Animals; Cecum; Cytokines; Disease Models, Animal; Guanidines; Ligation; Male; Mice; Nitric Oxide; N | 2015 |
Optimal study design for pioglitazone in septic pediatric patients.
Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Computer Simulation; Diabetes | 2011 |
Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture.
Topics: Adipocytes; Adiponectin; Animals; Cecum; Chemokine CCL2; Disease Models, Animal; Gene Expression; Hy | 2011 |
Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis.
Topics: Animals; Apolipoproteins E; Cytokines; Enzyme-Linked Immunosorbent Assay; Hypoglycemic Agents; Infla | 2008 |